subgroup analysis of pearls/keynote-091: pd-l1 expression and outcomes of pembrolizumab
Published 2 years ago • 652 plays • Length 3:18Download video MP4
Download video MP3
Similar videos
-
1:57
keynote 091: adjuvant pembrolizumab - onctalk lung 2023
-
4:48
keynote-091 and impower010: adjuvant chemotherapy for nsclc
-
5:45
subgroup analysis of the topaz-1 study by primary tumor location
-
7:31
outcomes of first-line pembrolizumab monotherapy for pd-l1–positive metastatic nsclc
-
0:56
pembrolizumab and the significance of pd-l1 for lung cancer
-
1:22
updated outcomes of keynote-010 of pembrolizumab for nsclc
-
2:31
a subgroup analysis of the secombit trial
-
3:47
a keynote on pd-l1 as a predictive biomarker of immunotherapy response: a complex picture
-
1:02:49
pd-l1/pd-1 cancer immunotherapy and new targets - gordon freeman, phd
-
4:00
cancer immunotherapy - pd-1 and pd-l1
-
2:07
immune checkpoint inhibitors, the next generation cancer therapy - creative biolabs
-
5:06
subgroup analysis of oak trial data supports use of atezolizumab in patients with nsclc
-
3:28
keynote-775 subgroup analysis in advanced endometrial cancer
-
1:48
results of keynote-024 trial of pembrolizumab in nsclc
-
10:20
pd-l1 testing in advanced lung cancer
-
2:19
the future of anti-pd-1 therapies in the nsclc treatment landscape
-
3:13
latest data from keynote 42: pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...
-
1:05
differences of response to io /- chemotherapy or io in nsclc depending on pd-l1 expression levels
-
3:42
first line pembrolizumab in pd-l1 tps 90% nsclc
-
1:25
a real-world analysis on pembro monotherapy versus pembro chemotherapy for never-smoking nsclc
-
2:56
keynote-010: pembrolizumab, anti-pd-1, for advanced nsclc with pd-l1 expression
-
2:31
differences in treating lung cancer with adjuvant and neoadjuvant immunotherapy